0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover710.61%IV-109.21%PremiumDec 20, 2024Expiry Date2.61Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3414Delta0.0911Gamma0.65Leverage Ratio-0.0362Theta-0.0020Rho-0.22Eff Leverage0.0021Vega
Stereotaxis Stock Discussion
Stereotaxis Inc: Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's National Medical Products Administration (NMPA) has approved the Genesis RMN® System. This approval enables the commercialization of advanced robotic technology for minimally-invasive procedures in China. MicroPort EP will lead the commercial launch through its existing electrophysiology sales teams. The approval is part of a broader...
Benzinga· 3 mins ago
Onward!
Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has achieved significant milestones for its next-generation robotic system, GenesisX. The company has obtained CE mark in Europe and submitted a 510(k) application to the FDA in the US. GenesisX builds upon the established benefits of Robotic Magnetic Nav...
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
NEWS
First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
No comment yet